OrbiMed Genesis GP LLC
CIK 1808744 · last filed 2026-06-15
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
ALPN price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
NEW YORK, NY 10022
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| STTK | Director | 1,051,021 | $5.54 | $5.82M | $0 | 2 | 2026-06-15 |
| QTTB | Director | 625,000 | $8.45 | $5.28M | $45.00M | 1 | 2026-06-01 |
| IMA | Director | 753,062 | $4.05 | $3.05M | $0 | 2 | 2026-04-16 |
| EWTX | Director | 14,809,075 | $39.17 | $580.07M | $30.00M | 1 | 2025-04-04 |
| IRON | Director | 746,171 | $77.66 | $57.95M | -$12.57M | 2 | 2025-03-26 |
| Enliven Therapeutics, Inc. (IMRA) Delisted | Director | 7,663,349 | $14.59 | $111.81M | -$68.63M | 2 | 2024-05-20 |
| ALPINE IMMUNE SCIENCES, INC. (ALPN) Delisted | Director | 2,270,930 | $64.97 | $147.54M | -$86.02M | 1 | 2023-12-29 |
| PMVP | 10%+ Owner | 6,475,291 | $1.13 | $7.32M | -$587.3K | 1 | 2023-11-24 |
| Damora Therapeutics, Inc. (GLTO) Delisted | 10%+ Owner | 25,242 | $28.69 | $724.2K | -$5.44M | 4 | 2023-08-17 |
| CMPX | Director | 15,219,994 | $0.75 | $11.37M | $5.13M | 2 | 2022-11-10 |
| Sierra Oncology, Inc. (SRRA) Delisted | Director | 0 | $54.99 | $0 | $0 | 1 | 2022-07-01 |
| ImageneBio, Inc. (IKNA) Delisted | Director | 174,841 | $17.16 | $3.00M | -$3.38M | 1 | 2022-06-24 |
| Theseus Pharmaceuticals, Inc. (THRX) Delisted | Director | 16,384,235 | $4.06 | $66.52M | $31.33M | 2 | 2022-01-13 |
| JANX | Director | 2,760,366 | $16.69 | $46.07M | $36.00M | 1 | 2021-06-16 |
Recent Filings · Page 2 of 3
24 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-11-24 | PMVP | Sell (S) | −263,358 | -$587.3K | EDGAR |
| 2023-08-17 | Damora Therapeutics, Inc. (GLTO) Delisted | Sell (S) | −4,113,400 | -$3.09M | EDGAR |
| 2023-04-17 | Damora Therapeutics, Inc. (GLTO) Delisted | Sell (S) | −342,405 | -$641.3K | EDGAR |
| 2023-04-12 | Damora Therapeutics, Inc. (GLTO) Delisted | Sell (S) | −337,685 | -$606.8K | EDGAR |
| 2023-04-07 | Damora Therapeutics, Inc. (GLTO) Delisted | Sell (S) | −513,150 | -$1.11M | EDGAR |
| 2023-02-27 | Enliven Therapeutics, Inc. (IMRA) Delisted | Grant (A) | +23,698,716 | $0 | EDGAR |
| 2023-01-03 | — | Other (J) | +8,643,764 | $0 | |
| 2022-11-10 | CMPX | Buy (P) | +1,206,000 | $3.87M | EDGAR |
| 2022-07-01 | Sierra Oncology, Inc. (SRRA) Delisted | Disp (D) | −7,859,080 | -$432.25M | EDGAR |
| 2022-06-24 | ImageneBio, Inc. (IKNA) Delisted | Buy (P) | −756,675 | -$3.38M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.